Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

After a full year of evaluation, patients taking Mounjaro lost 15.3% of their starting weight, compared to almost half of that — 8.3% — while taking Ozempic for 12 months.

“Individuals with overweight or obesity treated with tirzepatide (Mounjaro, Zepbound) were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared with those treated with semaglutide (Ozempic, Wegovy),” the authors wrote. 

In this large clinical analysis of US adults with overweight or obesity who initiated tirzepatide or semaglutide treatment, those receiving tirzepatide were more likely to achieve 5% or greater, 10% or greater, and 15% or greater weight loss and experienced larger reductions in body weight at 3, 6, and 12 months. To our knowledge, this study represents the first clinical comparative effectiveness study of tirzepatide and semaglutide in adults with overweight or obesity.

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080